P3 Health Partners (NASDAQ:PIII) Major Shareholder Hudson Vegas Investment Spv, L Sells 50,000 Shares

P3 Health Partners Inc. (NASDAQ:PIII) major shareholder Hudson Vegas Investment Spv, L sold 50,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $16.48, for a total transaction of $824,000.00. Following the sale, the insider directly owned 48,959 shares in the company, valued at $806,844.32. This trade represents a 50.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

P3 Health Partners Stock Performance

PIII stock opened at $11.69 on Thursday. The firm has a market cap of $84.69 million, a PE ratio of -0.35 and a beta of 1.63. The firm’s fifty day moving average is $11.00 and its 200 day moving average is $6.54. P3 Health Partners Inc. has a one year low of $1.52 and a one year high of $16.89.

P3 Health Partners (NASDAQ:PIII) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.26. The firm had revenue of $386.38 million during the quarter, compared to analyst estimates of $377.80 million.

Institutional Trading of P3 Health Partners

An institutional investor recently bought a new position in P3 Health Partners stock. Lido Advisors LLC bought a new position in shares of P3 Health Partners Inc. (NASDAQ:PIII) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned approximately 0.15% of P3 Health Partners as of its most recent SEC filing. Hedge funds and other institutional investors own 7.75% of the company’s stock.

Analyst Upgrades and Downgrades

PIII has been the subject of a number of analyst reports. Wall Street Zen raised P3 Health Partners to a “hold” rating in a report on Saturday, July 4th. UBS Group set a $14.00 price objective on P3 Health Partners in a report on Friday, May 15th. Weiss Ratings raised P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. Lake Street Capital restated a “buy” rating and issued a $23.00 price objective on shares of P3 Health Partners in a research report on Tuesday. Finally, TD Cowen reaffirmed a “hold” rating and set a $14.00 target price (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.00.

P3 Health Partners Company Profile

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.